Publications by authors named "Andrew A Girard"
Article Synopsis
- The HELIOS-B trial is the first randomized study testing a gene silencing treatment, vutrisiran, for transthyretin cardiac amyloidosis (ATTR-CM) against a placebo.
- Vutrisiran showed a 28% reduction in all-cause mortality and recurrent cardiovascular events, along with significant improvements in patient-reported outcomes like the 6-minute walk test and quality of life metrics.
- Both treatment and control groups had similar rates of discontinuation and adverse events, indicating vutrisiran is well tolerated among patients.
To determine the blood pressure independent effects of spironolactone on left atrial (LA) size and function in patients with resistant hypertension (RHTN). Patients with RHTN (n = 36, mean age 55 ± 7) were prospectively recruited. Spironolactone was initiated at 25 mg/day and increased to 50 mg/day after 4 weeks.
View Article and Find Full Text PDFBackground: Left atrial (LA) strain is impaired in left ventricular (LV) diastolic dysfunction, associated with increased LV end diastolic pressure (LVEDP). In patients with preserved LV ejection fraction (LVEF), coronary artery disease (CAD) is known to impair LV diastolic function. The relationship of LVEDP with CAD and impact on LA strain is not well studied.
View Article and Find Full Text PDFTraumatic central retinal vein occlusion following a hawk attack to the posterior cranium.
Am J Ophthalmol Case Rep
December 2021
Purpose: We describe a patient who developed a central retinal vein oculsion following a diving hawk attack to her posterior cranium.
Observations: A 50-year-old female presented with decreased visual acuity and color perception in the left eye following a diving hawk attack to her right-posterior parietal cranium. Medical history was significant for well-controlled type 2 diabetes, hyperlipidemia, and obesity.